StockMacro
Menu

MBX Biosciences

$49.55 +56% in 6 monthsMarket cap $2.5B

MBX on XNAS, Health Care, MBX Biosciences, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 83% in 12 months as news coverage hit 7.3 times its usual week.

  • BadNet loss $145.1M over 12 months and free cash outflow $99.3M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

Industry
Pharmaceutical preparations (Health Care)
Employees
63
Website
mbxbio.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $62.4M.
Quarter to 31 Mar 2023: revenue –, net income -$5.9MQuarter to 30 Jun 2023: revenue –, net income -$7.6MQuarter to 30 Sep 2023: revenue –, net income -$10.2MQuarter to 31 Dec 2023: revenue –, net income -$8.9MQuarter to 31 Mar 2024: revenue –, net income -$12.3MQuarter to 30 Jun 2024: revenue –, net income -$15.9MQuarter to 30 Sep 2024: revenue –, net income -$18.1MQuarter to 31 Dec 2024: revenue –, net income -$15.6MQuarter to 31 Mar 2025: revenue –, net income -$23.9MQuarter to 30 Jun 2025: revenue –, net income -$19.4MQuarter to 30 Sep 2025: revenue –, net income -$21.6MQuarter to 31 Dec 2025: revenue –, net income -$22.1MQuarter to 31 Mar 2026: revenue –, net income -$23.5MQuarter to 30 Jun 2026: revenue –, net income -$37.1MQuarter to 30 Sep 2026: revenue –, net income -$62.4M
31 Mar 2023RevenueNet incomeNet losstallest bar $62.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$62.4M
30 Jun 2026–-$37.1M
31 Mar 2026–-$23.5M
31 Dec 2025–-$22.1M
30 Sep 2025–-$21.6M
30 Jun 2025–-$19.4M
31 Mar 2025–-$23.9M
31 Dec 2024–-$15.6M
30 Sep 2024–-$18.1M
30 Jun 2024–-$15.9M
31 Mar 2024–-$12.3M
31 Dec 2023–-$8.9M
30 Sep 2023–-$10.2M
30 Jun 2023–-$7.6M
31 Mar 2023–-$5.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$145.1M -$80.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.02 $7.68
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -33.7% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$99.3M -$78.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $481.6M $391.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$481.6M (net cash) -$391.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $9.52
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.2 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
MBX BiosciencesMBX (this company) $2.5Bloss–––
IDEAYA BiosciencesIDYA $2.5Bloss67.6––
XencorXNCR $2.5Bloss12.4+34%-58.8%
Prestige Consumer HealthcarePBH $2.4B15.22.0+5.1%13.3%
Arcus BiosciencesRCUS $2.2Bloss22.5-58%-453%
PerrigoPRGO $2.2Bloss0.54-4.5%-43.3%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$288K

bought $0, sold $288K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+11%

189 13F filers vs 171

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

55.4M shares held by 13F filers (30 Sep 2026) of 49.7M outstanding (5 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.6%

4.3M shares sold short (30 Oct 2026) of 49.7M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.9

4.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-3.1%

4.4M shares sold short in the report before, 4.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

11

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $49.55 on 20 Nov 2026, +83% over 12 months (12-month range $26.92 to $70.70)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $2.5M in the last 12 months (the 12 months before: $15.1M).
Capital spending per quarter. Capital spending $1.2M in the latest quarter, +198% on a year earlier.
Institutional holders (13F filers). 189 13F filers reported holding it in the latest 13F quarter, +66% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
22 Oct 20268-K and other filingsDirector or officer change
22 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Jul 20268-K and other filingsDirector or officer change
5 Jun 20268-K and other filingsDirector or officer change
5 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Feb 20268-K and other filingsDirector or officer change
22 Jan 20268-K and other filingsDirector or officer change
6 Nov 20258-K and other filingsDirector or officer change
6 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Oct 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 12.5M)
22 Sep 20258-K and other filingsRegistered new securities for sale (S-1)
6 Jun 20258-K and other filingsDirector or officer change
7 Apr 20258-K and other filingsDirector or officer change
7 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Sep 2024Sharp changeClustered insider buying: clustered insider buying (6 independent filers, 6 filing(s) in 30 days, value_usd total 60.0M)
9 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
30 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
23 Aug 20248-K and other filingsRegistered new securities for sale (S-1)
18 Nov 20228-K and other filingsPrivate placement of securities (Form D)
Insider net buying (open market)
Month from 1 Sep 2024: $60.0M published
Month from 1 Feb 2025: $2.6M published
Month from 1 Apr 2025: $45K published
Month from 1 Oct 2025: $12.5M published
Month from 1 Mar 2026: $526K published
Month from 1 May 2026: -$2.7M published
Month from 1 Aug 2026: -$24K published
Month from 1 Nov 2026: -$288K published
Capital spending per quarter
Quarter ended 31 Dec 2023: $55K; public on 18 Mar 2025
Quarter ended 31 Mar 2024: $273K; public on 13 May 2025
Quarter ended 30 Jun 2024: $452K; public on 8 Aug 2025
Quarter ended 30 Sep 2024: $57K; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $92K, +67% on a year earlier; public on 18 Mar 2025
Quarter ended 31 Mar 2025: $30K, -89% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $707K, +56% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $399K, +600% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $793K, +762% on a year earlier; public on 13 Mar 2026
Quarter ended 31 Mar 2026: $437K, +1357% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $901K, +27% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.2M, +198% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
30 Sep 2024 report: 40; public on 14 Nov 2024
31 Dec 2024 report: 61; public on 14 Feb 2025
31 Mar 2025 report: 77; public on 15 May 2025
30 Jun 2025 report: 85; public on 14 Aug 2025
30 Sep 2025 report: 114; public on 14 Nov 2025
31 Dec 2025 report: 134; public on 17 Feb 2026
31 Mar 2026 report: 154; public on 15 May 2026
30 Jun 2026 report: 171; public on 14 Aug 2026
30 Sep 2026 report: 189; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $268K (12 Nov 2026), higher than 92% of its own history.
  • Insider net buying (open market): Insiders sold a net $2.5M in the last 12 months (the 12 months before: $15.1M).
  • Capital spending per quarter: Capital spending $1.2M in the latest quarter, +198% on a year earlier.
  • Institutional holders (13F filers): 189 13F filers reported holding it in the latest 13F quarter, +66% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 29 insider trades

Last 90 days: 2 sales, $288K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Steven L. HoerterChairman, President and CEOSell4,893$54.82$268KForm 4
5 Nov 2026Salomon AzoulayChief Medical OfficerSell373$53.96$20KForm 4
5 Aug 2026Salomon AzoulayChief Medical OfficerSell370$65.77$24KForm 4
11 May 2026Salomon AzoulayChief Medical OfficerSellplanned in advance (10b5-1); after exercising options70,003$38.36$2.7MForm 4
8 May 2026Salomon AzoulayChief Medical OfficerSell231$29.54$7KForm 4
8 May 2026P. Kent HawrylukPresident & CEOSell607$29.54$18KForm 4
16 Mar 2026P. Kent HawrylukPresident & CEOBuy18,500$28.41$526KForm 4
21 Oct 2025P. Kent HawrylukPresident & CEOBuy20,000$13.64$273KForm 4

189 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 39 opened a position, 19 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)7.4M14.8%$431.9M+2.0M+38%
Frazier Life Sciences Management, L.P.6.7M13.4%$389.9MNo change
Wellington Management Group LLP5.2M10.4%$302.7M+187K+3.8%
Paradigm Biocapital Advisors LP3.8M7.60%$221.2M+1.3M+50%
NEA Management Company, LLC3.6M7.28%$211.9MNo change
BlackRock, Inc.3.5M6.99%$203.6M+150K+4.5%
Orbimed Advisors LLC3.1M6.19%$180.2M-354K-10%
NVP Associates, LLC2.1M4.30%$125.2MNo change
Polar Capital Holdings Plc1.6M3.23%$94.0M-4,932-0.3%
Vanguard Capital Management LLC1.4M2.88%$83.9M-46K-3.1%

Company events

All 17 company events

In 12 months: 5 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
22 Oct 2026Director or officer change8-K
13 Jul 2026Director or officer change8-K
5 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
27 Feb 2026Director or officer change; Signed a major agreement8-K
22 Jan 2026Director or officer change8-K
6 Nov 2025Director or officer change8-K
26 Sep 2025Signed a major agreement8-K
22 Sep 2025Registered new securities for sale (S-1)S-1

11 open postings; careers site tracked since 20 Nov 2026. Most in Legal, policy & compliance 27%, Research & science 27%, Finance & accounting 9%, Operations & administration 9%.

PostedJobLocation
12 Nov 2026Director, IT Infrastructure and SecuritySecurityBurlington, MA
2 Nov 2026Clinical Scientist (Late Stage)Research & scienceBurlington, MA
22 Oct 2026Payroll SpecialistFinance & accountingBurlington, MA or Carmel, IN
21 Oct 2026Director, Clinical Operations (Obesity)Operations & administrationBurlington, MA
16 Oct 2026Associate Director, QA Oversight for QCTest, quality & reliabilityBurlington, MA
13 Oct 2026Scientist, Peptide ChemistryResearch & scienceGreater Boston Area
2 Oct 2026Senior Scientist, Drug SubstanceResearch & scienceBurlington, MA
1 Oct 2026Quality Systems & Compliance SpecialistLegal, policy & complianceBurlington, MA

The 5 newest of 90 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 22 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 22 Oct 2026Filings record

    Director or officer change

  3. 13 Jul 2026Filings record

    Director or officer change

  4. 5 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 5 Jun 2026Filings record

    Director or officer change

  6. 17 Mar 2026Insiders record

    Hawryluk P. Kent (President & CEO) bought 18,500 shares of MBX ($525,585) (dated 16 Mar 2026)

  7. 27 Feb 2026Filings record

    Director or officer change

  8. 22 Jan 2026Filings record

    Director or officer change

  9. 6 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 6 Nov 2025Filings record

    Director or officer change

  11. 22 Oct 2025Insiders change

    had 3 insiders buy $12.5M of its shares on the open market within 30 days (3 filings).

    Who bought: Hoerter Steven L., Hawryluk P. Kent.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $12.5M
    Window
    22 Sep 2025 to 22 Oct 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  12. 22 Oct 2025Insiders record

    Hawryluk P. Kent (President & CEO) bought 20,000 shares of MBX ($272,800) (dated 21 Oct 2025)

  13. 21 Oct 2025Insiders record

    Hoerter Steven L. (director) bought 20,000 shares of MBX ($265,000) (dated 20 Oct 2025)

  14. 1 Oct 2025Insiders record

    FHMLS X, L.P. (ten percent owner) and 4 other(s) bought 666,666 shares of MBX ($12.0M) (dated 30 Sep 2025)

  15. 22 Sep 2025Filings record

    Registered new securities for sale (S-1)

  16. 6 Jun 2025Filings record

    Director or officer change

  17. 11 Apr 2025Insiders record

    Pescovitz Ora H. (director) bought 7,693 shares of MBX ($45,312) (dated 10 Apr 2025)

  18. 7 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 7 Apr 2025Filings record

    Director or officer change

  20. 20 Feb 2025Insiders record

    OrbiMed Genesis GP LLC (director) and 2 other(s) bought 190,672 shares of MBX ($2.0M) (dated 19 Feb 2025)

  21. 20 Feb 2025Insiders record

    GORDON CARL L (director) bought 190,672 shares of MBX [same transaction as an earlier filing] (dated 19 Feb 2025)

  22. 6 Feb 2025Insiders record

    Hawryluk P. Kent (President & CEO) bought 50,000 shares of MBX ($534,500) (dated 5 Feb 2025)

  23. 18 Sep 2024Insiders change

    had 6 insiders buy $60.0M of its shares on the open market within 30 days (6 filings).

    Who bought: Aynechi Tiba, Sandell Scott D, Gordon Carl L, Heron Patrick J.

    See the evidence (6 source records)
    Independent buyers
    6
    Purchase filings (Form 4, code P)
    6
    Total bought
    $60.0M
    Window
    19 Aug 2024 to 18 Sep 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  24. 18 Sep 2024Insiders record

    Makhzoumi Mohamad (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  25. 18 Sep 2024Insiders record

    Behbahani Ali (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  26. 18 Sep 2024Insiders record

    Heron Patrick J (director) bought 625,000 shares of MBX ($10.0M) (dated 17 Sep 2024)

  27. 18 Sep 2024Insiders record

    Chang Carmen (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  28. 18 Sep 2024Insiders record

    GORDON CARL L (director) bought 750,000 shares of MBX ($12.0M) (dated 17 Sep 2024)

  29. 18 Sep 2024Insiders record

    NEA Partners 17, L.P. (ten percent owner) and 2 other(s) bought 500,000 shares of MBX ($8.0M) (dated 17 Sep 2024)

  30. 18 Sep 2024Insiders record

    Florence Anthony A. Jr. (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  31. 18 Sep 2024Insiders record

    ORBIMED ADVISORS LLC (director) and 2 other(s) bought 750,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  32. 18 Sep 2024Insiders record

    Yang Rick (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  33. 18 Sep 2024Insiders record

    Walker Paul Edward (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  34. 18 Sep 2024Insiders record

    SANDELL SCOTT D (ten percent owner) bought 500,000 shares of MBX ($8.0M) (dated 17 Sep 2024)

  35. 18 Sep 2024Insiders record

    BASKETT FOREST (ten percent owner) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  36. 18 Sep 2024Insiders record

    FHMLS X, L.P. (ten percent owner) and 3 other(s) bought 625,000 shares of MBX ($10.0M) (dated 17 Sep 2024)

  37. 18 Sep 2024Insiders record

    Aynechi Tiba (director) bought 750,000 shares of MBX ($12.0M) (dated 17 Sep 2024)

  38. 18 Sep 2024Insiders record

    Mathers Edward T (director) bought 500,000 shares of MBX [same transaction as an earlier filing] (dated 17 Sep 2024)

  39. 9 Sep 2024Filings record

    Registered new securities for sale (S-1)

  40. 30 Aug 2024Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 44 entries; narrow the window or the kind of data to see older ones.

Not listed: 39 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001776111
Ticker
MBX
Domain
mbxbio.com
Hq location
IN|CARMEL|46032 (1 unverified)
Name
MBX Biosciences, Inc.
  • SEC Form 13F institutional holdings81 data points30 Sep 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)48 records10 May 2019 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)180 data points31 Dec 2022 to 5 Nov 2026
  • SEC Form 4 insider transactions29 records, 52 data points17 Sep 2024 to 12 Nov 2026
  • FINRA short interest (twice monthly)152 data points30 Sep 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1100 data points13 Sep 2024 to 20 Nov 2026